Strategic merger Kapadi represents a merged platform combining OncoBay Clinical with Clinscience and Exom Group, signaling enhanced scale, integrated technology, and broader global oncology trial capabilities that could unlock larger, multi-site opportunities for pharmaceutical sponsors.

Immuno-oncology focus Specialization in immuno-oncology and cell therapy positions Kapadi as a go-to CRO for sponsors seeking expert support across complex cell-based programs, potentially winning business from companies advancing CAR-T, TCR, and combination immunotherapies.

End-to-end control Emphasis on integrated cell manufacturing, streamlined tech framework, and a trained site network suggests a compelling value proposition for sponsors needing end-to-end, compliant manufacturing and monitoring across global trials.

Recent client wins Active client acquisitions with Lymphoma Society and Hillstream BioPharma highlight momentum in oncology trials and regulatory development, presenting concrete reference cases to accelerate outreach to similar biotechs and pharma companies.

Growth opportunities Revenue in the low multi-millions range and an 11-50 employee base indicate a nimble organization with room to scale; sales conversations can target mid-size biotech firms seeking boutique CRO agility with deep oncology expertise and data-driven capabilities.